新股上市:生物制药公司Clearside Biomedical(CLSD)

Clearside Biomedical, Inc.(NASDAQ:CLSD)创立于2011年,总部位于美国佐治亚州Alpharetta,全职雇员21人,是一家生物制药公司,专注于慢性致盲眼病治疗药物的开发、研究。

新股上市:生物制药公司Clearside Biomedical(CLSD)

Clearside Biomedical(CLSD)美股百科:

Clearside Biomedical, Inc.的候选产品包括:

  1. CLS-1001:用于非感染性眼色素层炎相关的黄斑水肿治疗;
  2. CLS-1003:用于视网膜静脉阻塞相关的黄斑水肿治疗;
  3. CLS-1002:用于湿性年龄相关性黄斑变性的治疗。

Clearside Biomedical(CLSD)公司价值:

  • Develop technology that provides a ground breaking impact to medicine and superior care to patients.
  • Perform and deliver the highest quality with every task and product.
  • Fully exercise the full benefit of the technology/asset that is in our possession.
  • Focus as a team, debate each decision and fully support the direction.
  • Treat each other with honesty and mutual respect, and any disagreements will be voiced.
  • Facilitate a vibrant culture – we will celebrate success!

Clearside Biomedical(CLSD)美股投资:

Clearside Biomedical, Inc.于2016年6月2日与MBRXNH同日IPO,发行价7美金,发行720万股,募资5040万美金,股票代码:CLSD。

参考资料:

股票代码:
NASDAQ:CLSD公司官网http://clearsidebio.com
行情走势xueqiu.com/S/CLSD美股百科www.mg21.com/clsd.html

机构评级:

新股,暂无!

美股之家

发表评论

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen: